Phase 1 clinical study of SN-514 hydrogel in healthy adult volunteers
Latest Information Update: 28 Oct 2024
Price :
$35 *
At a glance
- Drugs SN 514 (Primary)
- Indications Burns; Diabetic foot ulcer; Leg ulcer; Pressure ulcer
- Focus Adverse reactions; First in man; Pharmacokinetics
- 15 Oct 2024 According to Serda Therapeutics media release, The study is being conducted in Irving, Texas, US, by RCTS (Reliance Clinical Testing Services), a part of ALS Limited.
- 15 Oct 2024 New trial record
- 29 Jul 2024 Status changed from recruiting to completed.